Skip to content

A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.

A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07174024
Acronym
Nb-UVB
Enrollment
30
Registered
2025-09-15
Start date
2025-01-20
Completion date
2025-08-23
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

blue light emitting diode

Brief summary

A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.

Detailed description

A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.

Interventions

type of phototherapy

DEVICEblue light emitting diode

type of diode

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All age group. * Both genders. * Subjects with stable non-segmental vitiligo (≥2 patches) acral or non-acral patches of diameter ≤ 2cm.

Exclusion criteria

* Prior treatment with laser therapies for at least 3 months * Recent exfoliation procedures. * Recent surgical procedures. * Poor skin conditions including keloids. * Hypersensitivity to light ( visible and near-infrared). * Medications that make users more sensitive to light. * Anticoagulant and immunosuppressive treatments. * Gestations or breastfeeding. * A personal or family history of skin cancer. * Unstable vitiligo (older lesions have not progressed for the last 1 years and lack of Koebner phenomena ).

Design outcomes

Primary

MeasureTime frameDescription
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.48 weeksAssess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026